Indivior declares $8.13 special dividend
- Indivior Pharmaceuticals (NASDAQ:INDV) declared a contingent special cash dividend of $8.13 per share.
- The dividend depends on the completion of Indivior’s pending merger with Supernus Pharmaceuticals.
- Eligible shareholders of record as of October 30, 2026, are expected to receive payment after the merger closes.
Indivior Pharmaceuticals (NASDAQ:INDV) declared a contingent special cash dividend of $8.13 per share, with payment dependent on the completion of its pending merger with Supernus Pharmaceuticals.
The dividend will be paid to holders of record of Indivior common stock as of October 30, 2026, and to certain equity award holders through equivalent payments upon vesting.
The dividend is expected to be paid on or about November 6, 2026, if the merger closes as expected on or around November 2, 2026, following required shareholder approvals and satisfaction or waiver of merger agreement conditions.
Indivior develops medicines focused on addiction treatment and related health conditions, including products used in opioid dependence treatment.
The company said Supernus Pharmaceuticals shareholders will not receive the special dividend on any Indivior shares issued as merger consideration, while the dividend remains subject to the merger closing.
Frequently asked questions
More from United States
AbbVie revenue increases 10.3% to $17.4 billion in third quarter
Sensient Q3 revenue rockets 10.6% to $455.8 million
Cameco Q3 adjusted loss reaches CA$2 million as uranium output falls
Kite Realty Q3 loss narrows to $13.3 million as NOI grows
Largo cuts 2026 vanadium production outlook to 9,500–10,500 tonnes
nVent Q3 sales jump 44% as shares fall despite higher revenue
